Kidney Cancer

Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

The latest drugs for advanced kidney cancer are stirring optimism.

The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.

In an interview with CURE, Badani, a professor of Urology at Mount Sinai Hospital, discusses the benefits of robotic surgery in RCC.

Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma.

Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.

James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.

David McDermott, M.D. discusses new advances made to treat kidney cancer.

An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.

A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.

A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.

Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.

Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.

CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.